A plain-English guide to the new long-acting amylin research peptide: how it works, how it compares, and how to source it in Australia.
View Eloralintide →
What is eloralintide? It’s one of the newest and most closely watched compounds in metabolic research: a long-acting peptide built to act on the amylin receptor, part of the body’s natural fullness and appetite signalling system. It moved quickly from early trials into Phase 3 research, which is why its name now comes up so often alongside better-known metabolic peptides.
Eloralintide (development code LY3841136) is an investigational research compound: not approved for therapeutic use by the TGA or any other regulator, and supplied strictly for laboratory and research purposes. This guide walks through what it is, how it differs from similar peptides, and what to look for when sourcing it.
What Is Eloralintide and How Does It Work?
To understand eloralintide, it helps to start with amylin. Amylin is a natural hormone released by the pancreas alongside insulin after a meal. In research, it’s linked to three connected signals: the feeling of fullness, slower gastric emptying, and the balance of hormones released after eating.
Natural amylin breaks down within minutes, so researchers have spent years designing longer-lasting versions. Eloralintide is one of the newest of these, and the research interest centres on a few design features:
- Amylin receptor selectivity: some earlier amylin-based peptides also act strongly on calcitonin receptors. Eloralintide was designed to favour the amylin receptor, giving researchers a cleaner way to study amylin signalling on its own.
- Long-acting design: it was built for a long duration of action, suited to once-weekly protocols in research settings.
- A separate pathway from incretins: amylin signalling works differently from the GLP-1 and GIP pathways, so eloralintide is studied both on its own and alongside incretin-based compounds.
In short, eloralintide is studied as a focused, long-acting tool for exploring the amylin pathway in metabolic research.
Eloralintide vs Other Metabolic Research Peptides
The easiest way to see where eloralintide fits is to line it up against the other peptides researchers most often compare it with:
| Compound | Type | Main receptor targets |
|---|---|---|
| Eloralintide | Long-acting amylin analogue | Amylin receptor (selective) |
| Cagrilintide | Long-acting amylin analogue | Amylin and calcitonin receptors |
| Pramlintide | Short-acting amylin analogue | Amylin receptors |
| Retatrutide | Triple agonist | GLP-1, GIP and glucagon receptors |
Reading down the table, the difference is clear. Cagrilintide is eloralintide’s closest relative, but it acts on calcitonin receptors as well. Retatrutide works on a completely different set of receptors. That’s why researchers often study amylin peptides and incretin peptides together, rather than treating them as alternatives.
The Research Landscape
Eloralintide has progressed quickly. After early-phase studies, a 48-week Phase 2 clinical trial was published in The Lancet in late 2025, examining a range of metabolic markers across several dose levels compared with placebo. On the strength of that work, Phase 3 research is now underway, and eloralintide is also being studied in combination with incretin-based compounds.
These are published research outcomes from clinical studies, not results for any individual and not therapeutic claims. Eloralintide remains investigational worldwide.
Note: the research picture is moving fast. Confirm the latest published data before citing specifics.
Handling & Storage
Eloralintide is supplied as a lyophilised (freeze-dried) powder. Keeping it stable is straightforward if you follow a few basics:
- As a powder: store refrigerated (2–8°C).
- Once reconstituted: store refrigerated (2–8°C).
- Reconstitution is done gently with bacteriostatic water. No aggressive shaking, which can damage the peptide’s structure.
Sourcing Eloralintide for Research in Australia
At Pureform Labs, eloralintide is supplied for laboratory research use only, from local Australian stock. Orders placed and paid before 1pm AEST on weekdays are dispatched from Sydney the same business day.
You can view the current listing on the Eloralintide product page. COAs for our tested products are published on our Lab Results page, and testing documentation for eloralintide will be added there once completed.
Related research peptides
Researchers working with eloralintide often also look at Cagrilintide, another long-acting amylin peptide, and Retatrutide, one of the most widely studied metabolic peptides. You can also read our Retatrutide research guide.
Research use only. This article is provided for educational and informational purposes about a compound used in scientific research. Eloralintide is not a therapeutic good and has not been evaluated or approved by the Therapeutic Goods Administration (TGA) or any other regulatory body. It is not intended for human or veterinary use, diagnosis, treatment, or the prevention of any condition. Nothing in this article constitutes medical advice or a therapeutic claim. All products are supplied strictly for laboratory and research purposes.
